BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
10/13/2015 10:26:00 AM | Browse: 1286 | Download: 2275
Publication Name World Journal of Clinical Oncology
Manuscript ID 19752
Country Italy
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Editorial
Article Title Current and future treatment of anaplastic lymphoma kinase-rearranged cancer
Manuscript Source Invited Manuscript
All Author List Luca Mologni
Funding Agency and Grant Number
Funding Agency Grant Number
Italian Association for Cancer Research AIRC 2013 IG-14249
Corresponding Author Luca Mologni, PhD, Molecular Oncology Lab, Department Health Sciences, University of Milano-Bicocca, Via Cadore 48, 20900 Monza, Italy. luca.mologni@unimib.it
Key Words Anaplastic lymphoma kinase tyrosine kinase receptor; Protein kinase inhibitors; Drug resistance; Crizotinib; Drug combinations
Core Tip In this Editorial article, I discuss the issue of anaplastic lymphoma kinase (ALK) driven cancer and its specific treatment with selective ALK tyrosine kinase inhibitors. The problem of acquired drug resistance is shortly reviewed and clinical data with novel investigational ALK inhibitors are presented. The possibility of specific combination therapies is briefly discussed.
Publish Date 2015-10-13 10:26
Citation Mologni L. Current and future treatment of anaplastic lymphoma kinase-rearranged cancer. World J Clin Oncol 2015; 6(5): 104-108
URL http://www.wjgnet.com/2218-4333/full/v6/i5/104.htm
DOI http://dx.doi.org/10.5306/wjco.v6.i5.104
Full Article (PDF) WJCO-6-104.pdf
Full Article (Word) WJCO-6-104.doc